UroGen Pharma Ltd. reiterated revenue guidance for the full year 2023. The Company reiterates anticipated full year 2023 net product revenues from JELMYTO to be in the range of $76 million to $86 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.24 USD | +3.04% | +0.15% | -11.73% |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
May. 13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.73% | 478M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- UroGen Pharma Ltd. Reiterates Revenue Guidance for the Full Year 2023